The hepatopulmonary syndrome

Baillieres Best Pract Res Clin Gastroenterol. 2000 Dec;14(6):1033-48. doi: 10.1053/bega.2000.0145.

Abstract

The hepatopulmonary syndrome is a triad of liver disease, increased alveolar-arterial oxygen gradient and intrapulmonary vascular dilatations. Manifestations include orthodeoxia, platypnoea and hyperdynamic circulation. Intrapulmonary vascular abnormalities, perhaps mediated by nitric oxide, cause hypoxaemia by shunting, a perfusion-diffusion defect, and ventilation-perfusion mismatching. Contrast-enhanced echocardiography is the method of choice for demonstrating pulmonary vascular abnormalities, although perfusion lung scanning is a more specific and sensitive test. Angiography is best reserved for patients with poor response to 100% oxygen and defines whether vascular dilatations are of the diffuse 'spongy' type or, less commonly, discrete arteriovenous communications amenable to embolization. About 80% of patients with the hepatopulmonary syndrome eventually have improved oxygenation after liver transplantation, thereby making worsening hypoxaemia the primary indication for transplantation in many instances. Nevertheless, severe hypoxaemia carries a peri-operative mortality of 30% and reliable predictors of successful outcome after transplantation remain to be determined.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Female
  • Hepatopulmonary Syndrome / diagnosis*
  • Hepatopulmonary Syndrome / mortality
  • Hepatopulmonary Syndrome / therapy*
  • Humans
  • Male
  • Prognosis
  • Severity of Illness Index
  • Survival Rate